0021-972X/06/$15.00/0 Printed in U.S.A.

The Journal of Clinical Endocrinology & Metabolism 91(3):899 905 Copyright 2006 by The Endocrine Society doi: 10.1210/jc.2005-1927

Prospective Study of Changes in Bone Mineral Density and Turnover in Children after Hematopoietic Cell Transplantation
Anna Petryk, Tracy L. Bergemann, Kristen M. Polga, Kami J. Ulrich, Susan K. Raatz, David M. Brown, Leslie L. Robison, and K. Scott Baker
Departments of Pediatrics (A.P., K.M.P., K.J.U., D.M.B., L.L.R., K.S.B.), Genetics, Cell Biology and Development (A.P.), Biostatistics (T.L.B.), Medicine (S.K.R.), and Laboratory Medicine and Pathology (D.M.B.), University of Minnesota, Minneapolis, Minnesota 55455
Context: Osteoporosis is common in adults after hematopoietic cell transplantation (HCT). The data on bone mineral density (BMD) in children after HCT are limited. Objective: The objective of the study was to determine the incidence, timing, magnitude, and possible predictors of bone loss in children after HCT. Patients and Design: The study population included 49 patients (age 518 yr) who were eligible to receive HCT at the University of Minnesota. The patients were evaluated at baseline, 100 d, 6 months, and 1 yr after HCT. Lumbar BMD (LBMD) was assessed by dualenergy x-ray absorptiometry. Results: The number of patients with osteopenia increased from 18% at baseline to 33% 1 yr after HCT, and with osteoporosis from 16 19%. Mean areal LBMD z-score decreased from 0.56 to 1.1 by 6 months (n 27) and at 1 yr was 0.94 (n 21), which was significant compared with standard normal distribution (P 0.004 and P 0.022, respectively). The absolute loss of bone mineral corresponded to a 5.3% reduction in areal LBMD and a 4.8% reduction in volumetric LBMD. The level of bone-specific alkaline phosphatase decreased by 30% by d 100 (P 0.009), followed by recovery toward baseline by 6 months. The level of osteocalcin greater than 6.5 ng/ml at d 100 predicted recovery from the initial bone loss by 1 yr. A reduction in LBMD at 6 months correlated with a cumulative dose of glucocorticoids. Conclusion: This study demonstrates that bone loss is common in children after HCT and is primarily due to suppression of bone formation. Further studies are necessary to validate osteocalcin as a predictive biomarker. (J Clin Endocrinol Metab 91: 899 905, 2006)

ITH THE USE of more effective therapy, including hematopoietic cell transplantation (HCT), more children are cured of their primary malignant or nonmalignant disorders and become long-term survivors. As a consequence of improved survival, the population of post-HCT patients is increasing and secondary effects of treatment become more prevalent. One of the metabolic complications of HCT is reduced bone mineral density (BMD) (13). Adequate bone mineral accretion is of particular importance in a pediatric population because it largely determines peak bone mass (4). The patients who do not reach the optimal BMD during childhood and adolescence are likely to be at risk for more pronounced subsequent age-related bone loss, which may predispose them to osteoporotic fractures and associated functional impairments during adulthood (5).
First Published Online December 13, 2005 Abbreviations: AA, Aplastic anemia; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; BCE, bone collagen equivalent; BMD, bone mineral density; BSAP, bone-specific alkaline phosphatase; CV, coefficient of variation; DXA, dual-energy x-ray absorptiometry; FA, Fanconi anemia; GHD, growth hormone deficiency; GVHD, graft vs. host disease; HCT, hematopoietic cell transplantation; ICTP, carboxylterminal cross-linked telopeptide of type I collagen; LBMD, lumbar BMD; LBMDA, areal LBMD; LBMDV, volumetric LBMD; OCN, osteocalcin; TBI, total body irradiation. JCEM is published monthly by The Endocrine Society (http://www. endo-society.org), the foremost professional society serving the endocrine community.

Studies in adult survivors of childhood cancer demonstrate that BMD is reduced at multiple skeletal sites and thus support the premise that inadequate BMD accrual during childhood may have long-term adverse effect on BMD in adulthood (6 9). The etiology of bone loss in patients undergoing treatment for malignancy is multifactorial and includes the negative effects of the chemotherapeutic agents, glucocorticoids, radiation, hypogonadism, abnormal vitamin D metabolism, reduced physical activity, graft vs. host disease (GVHD), and the malignant process per se (2, 6, 10 12). HCT has been implicated as an additional causative factor in bone loss, frequently compounding the negative effects of prior treatment of malignancy on bone metabolism (1, 2, 1317). In adults, significant bone loss occurs during the first 6 months after transplantation and is thought to be due to a combination of reduced bone formation and increased bone resorption (1, 15). The prevalence of osteopenia in adults after HCT is 39 53% and the prevalence of osteoporosis is 720% (13, 16, 18). To our knowledge, no prospective studies of BMD in a pediatric post-HCT population have been reported, but cross-sectional studies show that BMD is reduced in children after transplantation with mean BMD z-scores between 0.5 and 0.9, and as low as 4 (19 22). In a recent retrospective analysis conducted at a median of 5 yr after HCT, 26% of children had osteopenia and 21% had osteoporosis based on quantitative computed tomography (22).
899

900

J Clin Endocrinol Metab, March 2006, 91(3):899 905

Petryk et al. Bone Metabolism after Bone Marrow Transplant

The goals of this prospective study were to determine the incidence, timing, magnitude, and potential predictors of bone loss in children after HCT and to assess the changes in bone metabolism.
Subjects and Methods Study population
From January 2002 to January 2004 consecutive patients between 5 and 18 yr of age evaluated to undergo HCT for a blood disorder, cancer, metabolic disorder, or immune deficiency at the University of Minnesota were offered participation in the study. Of 77 eligible patients, 49 were prospectively enrolled (64%, 20 females and 29 males). Diagnoses included: Fanconi anemia (FA) (n 12), acute lymphoblastic leukemia (ALL) (n 10), acute myeloid leukemia (AML) (n 8), adrenoleukodystrophy (n 6), aplastic anemia (AA) (n 3), chronic myeloid leukemia (n 3), metachromatic leukodystrophy (n 3), non-Hodgkin lymphoma (n 1), combined variable immune deficiency (n 1), X-linked lymphoproliferative disorder (n 1), and Ewings sarcoma (n 1). The mean chronological age of the patients at the time of HCT was 10.2 3.7 yr (range 5.117.9), bone age 10.1 3.9; 12 females and 18 males were prepubertal at the time of enrollment. The mean height sd score was 0.34 1.61 (mean sd, n 49). Forty-seven patients received allogeneic HCT and two received autologous HCT. Preparative regimens consisted of cyclophosphamide, fludarabine, and 450 cGy single fraction total body irradiation (TBI) for all FA patients except one, who received only fludarabine and cyclophosphamide; cyclophosphamide and 600 cGy fractionated TBI for AA; cyclophosphamide and 1320 cGy fractionated TBI (1350 cGy for two patients with ALL) for ALL, AML, non-Hodgkin lymphoma; busulfan, cyclophosphamide for metabolic storage disorders (and one patient with AML); and fludarabine, melphalan for immune deficiencies. All patients received cyclosporine in combination with either methotrexate, mycophenolate, or methylprednisolone for GVHD prophylaxis. Total steroid exposure (expressed as prednisone equivalent in milligrams) included any steroid received with the HCT preparative regimen and for GVHD prophylaxis or treatment. The patients were evaluated before HCT and 100 d, 6 months, and 1 yr after HCT. The patients were examined for Tanner stage of pubertal development and growth parameters by a pediatric endocrinologist at all time points (23, 24). The primary endpoints of the study were the 6and 12-month changes in lumbar BMD (LBMD) by dual-energy x-ray absorptiometry (DXA). Changes in the markers of bone turnover were considered secondary endpoints. Of 49 patients enrolled in the study, 19 had DXA study at all three time points and an additional two patients had DXA study only at baseline and at 1 yr. Of 28 patients who did not return for a 1-yr follow-up DXA scan, 15 patients died, three patients had a relapse, and 10 patients were lost to follow up. The study was approved by the Institutional Review Board at the University of Minnesota. Informed consent was obtained before enrollment.

Laboratory tests and bone age

Serum levels of calcium, phosphorus, and magnesium were measured by standard methods. Bone formation was assessed by measuring the levels of bone-specific alkaline phosphatase (BSAP) and osteocalcin (OCN) (markers of early and mature osteoblast function) in the serum (27). Urinary N-telopeptide was used as a marker of bone resorption. BSAP and OCN were obtained in the early morning hours. BSAP was measured by a chemiluminescent immunoassay (DXi800; ARUP Laboratories, Salt Lake City, UT). Serum human OCN was measured by RIA (Diasorin, Inc., Stillwater, MN) between March 2002 and December 2003, and by chemiluminescence on the DPC Immulite analyzer (Diagnostic Products Corp., Los Angeles, CA) after January 2004 (due to discontinuation of the previous methodology). The sensitivity of RIA was 0.2 ng/ml, the inter and intraassay CVs were less than or equal to 11.2% at a mean of 4.8 ng/ml and less than or equal to 7.0% at a mean of 1.25 ng/ml, respectively. The sensitivity of chemiluminescence was 0.1 ng/ ml, and the inter and intraassay CVs were less than or equal to 5.6% at a mean of 6.3 ng/ml and less than or equal to 2.3% at a mean of 4.4 ng/ml, respectively. The correlation between RIA and chemiluminescent assay was 0.886 as determined by comparison of 53 samples. The values obtained by chemiluminescent assay were converted using linear correlation between the two assays. Collagen cross-linked N-telopeptide was measured in second void morning urine by ELISA/EIA (Osteomark NTx; Wampole Laboratories, Inc., Princeton, NJ). The sensitivity of the assay was 20 nm bone collagen equivalents (BCE), and the inter and intraassay CVs were less than or equal to 6.0% at a mean of 362 nm BCE and less than or equal to 19% at a mean of 26 nm BCE, respectively. Sex hormone levels were measured in females older than 10 yr and males older than 11 yr. Ultrasensitive estradiol was assessed by RIA (Diagnostic Systems Laboratories, Inc., Webster, TX). Testosterone, LH, and FSH levels were measured by a chemiluminescent immunoassay (Bayer Advia Centaur, Tarrytown, NY). Bone age was assessed based on the x-rays of the left hand and wrist using the method of Greulich and Pyle (28).

Dietary questionnaire
Dietary intake was assessed at baseline and 1 yr after HCT by a food frequency questionnaire designed for children (Block Kids 2000; Block Dietary Data Systems, Berkeley, CA). Analysis was performed using the Dietary Analysis System (version 4.01, National Cancer Institute, 1997).

Statistical methods
To analyze the association between one continuous measure and a continuous outcome, e.g. bone loss, linear regression analysis was used. This was simplified to a t test when comparing a continuous outcome between two groups. To compare the distribution of standardized BMD values to a normal population, we compared the collected data to simulated datasets from a standard normal distribution (25). Simulations were run 1000 times. Regression output was calculated to adjust L2L4 z-scores for bone age. To examine the pattern of BMD over time, a linear mixed effects model was used (29). Time is fit as a random effect because outcomes are repeated measures over time, and any other important covariates are fixed effects. This model was also used to look at biomarkers over time, such as OCN, N-telopeptide, or BSAP. A Student t test was used to compare steroid exposure between progression and recovery groups. To examine the absolute change in BMD over a 1-yr period, the observed changes in LBMD were compared with the expected increase within age and gender groups. A random effects model was fit to test whether the decrease over time was statistically significant. This mixed effects model fit time as a random effect and bone age as a continuous fixed effect. To explore the predictive power of OCN as a biomarker, we fit a classification and regression tree (30). This method seeks the optimal cut-off point to divide a continuous measure into binary variable by minimizing the residual deviance in the model. We used this method to determine the optimal threshold for OCN levels that would predict recovery of BMD between 6 12 months of the study.

Bone densitometry
Areal BMD (grams per square centimeter) of the lumbar spine (LBMDA) was measured in L2L4 region by DXA using a Lunar Prodigy (DXA, software version 5.0; General Electric, Madison, WI) at baseline, 6 months, and 12 months after HCT. Pediatric software was used for children less than 30 kg. The results of the scans are expressed as age-normalized z-scores (sd from the mean for age- and sex-matched controls) (25). Quality assurance was performed daily on the densitometer, and monthly phantom spine scans were performed to assess precision of measurements. The coefficient of variation (CV) for repeated measures of the phantom spine is 0.136. Volumetric LBMD (LBMDV) (grams per cubic centimeter) was calculated based on the LBMDA and the width of the lumbar vertebrae according to the following formula: LBMDA [4/( width] (25). Osteopenia was defined as a z-score between 1 and 2 sd below the mean, and osteoporosis was defined as a z-score more than 2 sd below the mean (22, 26). This classification was chosen for quantitative illustration of bone loss and for simplicity of nomenclature.

Petryk et al. Bone Metabolism after Bone Marrow Transplant

J Clin Endocrinol Metab, March 2006, 91(3):899 905

901

Results The changes in the LBMD

TABLE 2. Changes in LBMDA z-scores over time

L2-L4 z-scores based on chronological age Mean z-score 95% CI P value n

The average LBMDA z-score at baseline was 0.56, which was of borderline statistical significance compared with the general population (P 0.05). After HCT, there was a significant reduction in LBMDA (Table 1). By 6 months, mean LBMDA z-score decreased from 0.56 to 1.1 (n 27, P 0.004) and at 1 yr was 0.94 (n 21, P 0.022). The changes in z-score over time were significantly different from the standard normal distribution. LBMDA adjusted for bone age was also reduced compared with baseline by 0.51 sd at 6 months (P 0.002) and by 0.37 sd at 1 yr (P 0.01) (Table 1). Similar results were obtained when the analysis was restricted to the 19 patients with complete DXA follow-up (Table 2). A change in height SDS for these 19 patients was not statistically significant and did not correlate with a change in BMD z-score. This was also true for the entire study population, which argues against the possibility that poor growth alone could explain a reduction in LBMDA in these patients (31). The proportion of patients with osteopenia increased from 18.4% at baseline to 33.3% at 6 months, and the proportion of patients with osteoporosis increased from 16.3% at baseline to 25.9% at 6 months. At 1 yr, 52.3% of patients had either osteopenia (33.3%) or osteoporosis (19.0%). Because BMD in children increases over time, unlike in adults, a reduction in BMD z-score in children does not necessarily indicate an absolute loss of bone mineral, but rather an inadequate increase over time. The actual changes in LBMD were compared with the calculated expected increase within age and gender groups (25) (Fig. 1). The differences were statistically significant for both LBMDA (Fig. 1A) and LBMDV (Fig. 1B) (P 0.0001). The differences between expected and observed LBMD resulted not only from inadequate increase in BMD, but actual loss in LBMD (Table 3). The most significant bone loss occurred by 6 months and corresponded to 5.3% reduction in LBMDA and 4.8% reduction in LBMDV. Although post-HCT patients as a group showed a reduction in BMDA z-score over time, not every patient was affected to the same degree and, in some cases, bone mineralization was not affected at all (Fig. 2, A and B). Based on LBMDA z-scores at 6 months and 1 yr compared with baseline, the patients were divided into three groups: stable group, in which there was no significant decrease in LBMDA at 6 months or 1 yr; recovery group, in which there was a substantial LBMDA loss at 6 months, followed by the recovery of more than 50% of the initial loss; and progression group, in which LBMDA loss at 6 months was followed by
TABLE 1. Changes in LBMDA z-scores over time
L2-L4 z-scores based on chronological age Mean z-score 95% CI P value

Baseline 6 months 1 yr

0.63 1.09 0.84

( 1.10, ( 1.56, ( 1.29,

0.19) 0.66) 0.39)

0.13 0.014 0.049

19 19 19

either no recovery or the recovery of less than 50% by 1 yr. The hypothesis was that the recovery group might show different biochemical characteristics that favor recovery from the initial bone loss as opposed to the progression group.
The changes in the markers of bone turnover

The trends in the levels of the markers of bone formation and resorption over time are shown in Fig. 3. Only the changes in BSAP levels were statistically significant (P 0.009), although similar trends were seen for OCN and Ntelopeptide (Fig. 3A). The level of BSAP decreased by 30% after HCT and reached a nadir by d 100, followed by a progressive return toward baseline by 6 months and significantly above baseline by 1 yr. The decreases in OCN and N-telopeptide levels during the first 100 d after HCT were not statistically significant (P 0.15 and P 0.17, respectively). Although the changes in OCN levels were not significantly different when measured in all patients, they were significantly lower in the progression group than in the recovery group at all time points after HCT, with a nadir at d 100 (mean value of 2 ng/ml vs. 7.3 ng/ml, P 0.014) (Fig. 3B). No significant differences were found in BSAP or N-telopeptide levels between the recovery and progression groups.
Predictive value of OCN

The optimal value of OCN was 6.5 ng/ml at d 100. All six patients in the progression group had an OCN level less than 6.5 ng/ml (OCN level was not available for one patient at d 100); five of seven patients in the recovery group had an OCN level more than 6.5 ng/ml and two patients had OCN less than 6.5 ng/ml. Thus, a value of OCN less than 6.5 ng/ml had a 100% sensitivity and 71% specificity for the progression group. A predictive value of low OCN level was 75%.
Risk factors for bone loss

A positive relationship was detected between the cumulative dose of prednisone and the change in LBMDA z-score (R2 0.23, P 0.011). The progression group was exposed to higher doses of prednisone than the recovery group (5624 4657 vs. 1364 1323 mg, P 0.04). No relationship was found between radiation dose, body mass index, levels

L2-L4 z-scores adjusted for bone age n Coefficient 95% CI P value n

Bone age Baseline 6 months 1 yr

0.56 1.10 0.94

( 0.97, ( 1.61, ( 1.47,

0.15) 0.58) 0.41)

0.05 0.004 0.022

49 27 21

0.02 0.55 1.06 0.92

( ( ( (

0.03, 0.07) 1.05, 0.00) 1.65, 0.47) 1.57, 0.26)

0.48 0.06 0.002 0.01

49 49 27 21

902

J Clin Endocrinol Metab, March 2006, 91(3):899 905

Petryk et al. Bone Metabolism after Bone Marrow Transplant

FIG. 1. The differences between the observed and expected areal (A) and volumetric (B) LBMD. The black boxes represent the interquartile range of the data, with the median denoted by a white bar within its center. The hinges on the ends represent 95% confidence intervals if we were to assume that the data are normally distributed. Single black bars indicate outliers outside of the confidence intervals.

of phosphorus, magnesium, calcium, or dietary calcium, dietary vitamin D, and a change in LBMDA z-score when analyzed for all 49 patients and when compared between progression and recovery groups. Among patients who survived 1 yr after HCT, patients with ALL or AML were at higher risk of bone loss in the first 6 months than patients with FA or AA (decrease in LBMDA z-score of 0.83 compared with 0.2, P 0.04) (Fig. 3B). Contributing factors may have been higher steroid and radiation doses, although TBI doses cannot be directly compared because of differences in the fractionation schedules (single fraction for FA and fractionated for AA and leukemia).
Endocrine function

Both growth hormone deficiency (GHD) and hypogonadism can negatively affect BMD. A change in height SDS was not statistically significant for the 19 patients who were followed longitudinally at all study points. One of 19 patients was diagnosed with GHD before HCT (Fig. 2B). Because growth hormone stimulation testing was beyond the scope of this 1-yr study, it remains to be determined how many patients developed GHD after HCT, although based on the literature, the likelihood of GHD is high (17). One of seven females developed primary gonadal failure (FSH 40 IU/liter), and one of 12 males developed hypogonadotropic hypogonadism (Fig. 2B).
Discussion

Prospective studies in adult patients have shown that BMD decreases after HCT (1, 3, 14, 16). In adults, the most significant loss in BMD occurs during the first 6 months after HCT and is on average 2.0 5.7% in the lumbar region and 6.210% in the femoral neck region (32). This study demonstrates that HCT also has a major impact on bone health in children that is apparent 6 months after HCT with an average loss of 5.3% for LBMDA (or 0.54 sd) and 4.8% for LBMDV. Although bone loss stabilizes after 6 months in 50% of the
TABLE 3. Changes in LBMDA and LBMDV over time
LBMDA mean (g/cm2)
SD

LBMDV mean (g/cm3)

SD

Baseline 6 months 1 yr

0.773 0.732 0.791

0.223 0.226 0.202

0.292 0.278 0.302

0.064 0.060 0.043

49 27 21

patients, a substantial proportion of children continue to have either osteopenia (33.3%) or osteoporosis (19%) 1 yr after HCT. There was no significant correlation between gain in height SDS and changes in LBMDA score. Bone loss in adults after HCT is associated with an increased risk of fractures. Nontraumatic fractures occur in 10.6% of patients within 3 yr after HCT (16). Although the exact incidence of fractures in children after HCT is unknown, a reduction in BMD of 1 sd in children with a previous history of forearm fracture increases the risk of fractures by a factor of two, similar to the risk of fracture in adults (3335). Because routine radiographs were not performed in our patients (except for a bone age x-ray, which detected a fracture in one of the study patients), a diagnosis of fracture would have been based on self-reporting and would likely exclude less symptomatic cases, for example vertebral compression fractures. An additional potential adverse effect of vertebral fractures in children is impaired longitudinal growth. The observation that fractures in adults post-HCT occur at higher BMD than expected suggests that BMD alone may not be the only indicator of bone health in post-HCT patients, because it does not adequately reflect altered bone architecture due to transplant itself or transplant-related treatment (16). The relationship between inadequate bone mass increment during childhood and future osteoporosis during adulthood is implied by studies of young survivors of childhood cancer, but is limited by the lack of long-term prospective studies in children. Because BMD continues to increase during childhood (25), it is conceivable that some catch-up in BMD z-scores could occur depending on the age and pubertal status. A reduction in BMD is thought to be due to a combination of reduced bone formation and increased bone resorption (1, 15). Our data show a reduction in the markers of bone formation in children after HCT, similar to the reduction observed in adult patients (1, 14, 15), except that the decrease is more prolonged in some cases. Although, in adults, the level of OCN is above baseline at 3 months, in children, in the progression group the levels of OCN do not recover until 6 months. Unlike studies in adults, our study did not reveal an increase in bone resorption. On the contrary, we observed a trend toward a decrease in urinary N-telopeptide level after HCT, suggesting an adynamic bone state similar to that reported after renal transplantation (36). However, our eval-

Petryk et al. Bone Metabolism after Bone Marrow Transplant

J Clin Endocrinol Metab, March 2006, 91(3):899 905

903

FIG. 2. Changes in LBMDA z-scores in individual patients after HCT. A, Stable group: no significant decrease in BMDA z-score at 6 months or 1 yr compared with baseline. Recovery group: substantial BMDA loss at 6 months, followed by the recovery of more than 50% of the initial BMDA loss at 6 months. Progression group: substantial BMDA loss at 6 months and no recovery in BMDA or recovery of less than 50% between 6 12 months. B, Dx, diagnosis; Tanner stage pre/post, at baseline and 1 yr after HCT; Rad, radiation; ALD, adrenoleukodystrophy; CVID, combined variable immune deficiency; NHL, non-Hodgkin lymphoma; XLP, X-linked lymphoproliferative disorder; BU, busulfan; CY, cyclophosphamide; FL, fludarabine; ME, melphalan. *, Expressed as total dose in milligrams of prednisone equivalent received during study period. 1, GHD; 2, gonadal failure; 3, hypogonadotropic hypogonadism.

uation was limited to the urinary levels of N-telopeptide, and did not include a serum marker, carboxyl-terminal crosslinked telopeptide of type I collagen (ICTP), which was increased throughout the observation period in adult patients (1, 14, 15). Because bone formation is dependent on the proper balance between osteoblastic and osteoclastic activity, net bone loss in the absence of increased bone resorption points to reduced bone formation due to impaired osteoblastic activity as a primary cause of reduced BMD in children after HCT.

Osteoblasts are derived from bone marrow stromal cells and are thought to be of recipient origin unlike osteoclasts, which are derived from the peripheral mononuclear cells and are of donor origin (1). Myeloablative therapy before HCT has been shown to adversely affect osteogenic differentiation (37, 38). The ex vivo studies have demonstrated that differentiation of bone marrow stromal cells into osteoblasts is impaired after HCT even for as long as 6 10 yr (1, 37). Thus, the ability to regenerate osteoblast precursors within the host bone marrow may partially determine recovery in bone mass

FIG. 3. Changes in the levels of markers of bone turnover after HCT. A, The level of the osteoblast marker BSAP decreased after HCT reaching a nadir by d 100 (from 97.7 68.4 U/liter), followed by recovery toward baseline by 6 months and a significant increase above baseline by 1 yr. The decreases in OCN (from 6.25.8 ng/ml) and N-telopeptide (from 444.5317.7 nM BCE per millimoles of creatinine) levels during the first 100 d after HCT were not statistically significant (P 0.15 and P 0.17, respectively). B, The levels of OCN were significantly lower in the progression group than in the recovery group at all time points after HCT, with a nadir at d 100.

904

J Clin Endocrinol Metab, March 2006, 91(3):899 905

Petryk et al. Bone Metabolism after Bone Marrow Transplant

after HCT. Our finding that OCN levels were persistently lower in the progression group than in the recovery group is consistent with this model and likely reflects the degree to which stromal microenvironment is affected by myeloablation. The effects of chemotherapy and radiotherapy may be compounded by glucocorticoid exposure as well as hypogonadism and GHD (2, 1517). The negative effect of glucocorticoids on BMD was also shown in this study. In conclusion, although this study is limited by a small number of subjects and the heterogenous nature of the study population, it shows that bone loss is common in the first 6 months after HCT. The lack of demonstrable increase in bone resorption, compared with the adult studies, has potential implications for the management of osteoporosis in these patients. Further research needs to be done to investigate the mechanisms of bone loss after HCT to determine the contribution of bone resorption. Although bisphosphonates have been widely used in adults with osteoporosis, the antiresorptive agents may not be appropriate in the treatment of osteoporosis in children after HCT unless bone resorption is increased (36). Although no direct relationship was found between dietary calcium and vitamin D intake, it is prudent to recommend adequate vitamin D and calcium intake, weight bearing exercise, and appropriate hormonal replacement (39). The finding that higher OCN levels at d 100 can predict subsequent recovery from the initial bone loss may help target therapy to more vulnerable patients. However, this observation is based on a limited number of patients and further studies are necessary to validate OCN as a predictive biomarker.
Acknowledgments
We thank Dr. James Gurney, Dr. William Thomas, and Roger Olson for their help with study design and data collection, Linda Bailey from the Endocrine Laboratory at the University of Minnesota Medical Center, Fairview, for assistance with OCN and N-telopeptide assays, and Dixie Lewis for coordinating patient visits. We are thankful to Dr. Antoinette Moran for constructive comments on the manuscript. Received August 29, 2005. Accepted December 7, 2005. Address all correspondence and requests for reprints to: Anna Petryk, Department of Pediatrics, University of Minnesota, 13-124 PWB, MMC 404, 516 Delaware Street SE, Minneapolis, Minnesota 55455. E-mail: petry005@umn.edu. This work was supported by The Genentech Center for Clinical Research in Endocrinology (to A.P.), Childrens Cancer Research Fund, University of Minnesota (to A.P.), and National Institutes of Health Grants K23-CA85503 (to K.S.B.) and M01-RR00400.

References
1. Lee WY, Cho SW, Oh ES, Oh KW, Lee JM, Yoon KH, Kang MI, Cha BY, Lee KW, Son HY, Kang SK, Kim CC 2002 The effect of bone marrow transplantation on the osteoblastic differentiation of human bone marrow stromal cells. J Clin Endocrinol Metab 87:329 335 2. Ebeling PR, Thomas DM, Erbas B, Hopper JL, Szer J, Grigg AP 1999 Mechanisms of bone loss following allogeneic and autologous hemopoietic stem cell transplantation. J Bone Miner Res 14:342350 3. Schulte CM, Beelen DW 2004 Bone loss following hematopoietic stem cell transplantation: a long-term follow-up. Blood 103:36353643 4. Theintz G, Buchs B, Rizzoli R, Slosman D, Clavien H, Sizonenko PC, Bonjour JP 1992 Longitudinal monitoring of bone mass accumulation in healthy adolescents: evidence for a marked reduction after 16 years of age at the levels of lumbar spine and femoral neck in female subjects. J Clin Endocrinol Metab 75:1060 1065 5. Woolf AD, Pfleger B 2003 Burden of major musculoskeletal conditions. Bull World Health Organ 81:646 656

6. Aisenberg J, Hsieh K, Kalaitzoglou G, Whittam E, Heller G, Schneider R, Sklar C 1998 Bone mineral density in young adult survivors of childhood cancer. J Pediatr Hematol Oncol 20:241245 7. Arikoski P, Komulainen J, Voutilainen R, Riikonen P, Parviainen M, Tapanainen P, Knip M, Kroger H 1998 Reduced bone mineral density in long-term survivors of childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol 20:234 240 8. Brennan BM, Rahim A, Adams JA, Eden OB, Shalet SM 1999 Reduced bone mineral density in young adults following cure of acute lymphoblastic leukaemia in childhood. Br J Cancer 79:1859 1863 9. Baker KS, Gurney JG, Ness KK, Bhatia R, Forman SJ, Francisco L, McGlave PB, Robison LL, Snyder DS, Weisdorf DJ, Bhatia S 2004 Late effects in survivors of chronic myeloid leukemia treated with hematopoietic cell transplantation: results from the Bone Marrow Transplant Survivor Study. Blood 104:1898 1906 10. Atkinson SA, Halton JM, Bradley C, Wu B, Barr RD 1998 Bone and mineral abnormalities in childhood acute lymphoblastic leukemia: influence of disease, drugs and nutrition. Int J Cancer Suppl 11:3539 11. Atkinson SA, Fraher L, Gundberg CM, Andrew M, Pai M, Barr RD 1989 Mineral homeostasis and bone mass in children treated for acute lymphoblastic leukemia. J Pediatr 114:793 800 12. Arikoski P, Komulainen J, Riikonen P, Parviainen M, Jurvelin JS, Voutilainen R, Kroger H 1999 Impaired development of bone mineral density during chemotherapy: a prospective analysis of 46 children newly diagnosed with cancer. J Bone Miner Res 14:20022009 13. Kauppila M, Irjala K, Koskinen P, Pulkki K, Sonninen P, Viikari J, Remes K 1999 Bone mineral density after allogeneic bone marrow transplantation. Bone Marrow Transplant 24:885 889 14. Valimaki MJ, Kinnunen K, Volin L, Tahtela R, Loyttyniemi E, Laitinen K, Makela P, Keto P, Ruutu T 1999 A prospective study of bone loss and turnover after allogeneic bone marrow transplantation: effect of calcium supplementation with or without calcitonin. Bone Marrow Transplant 23:355361 15. Kang MI, Lee WY, Oh KW, Han JH, Song KH, Cha BY, Lee KW, Son HY, Kang SK, Kim CC 2000 The short-term changes of bone mineral metabolism following bone marrow transplantation. Bone 26:275279 16. Stern JM, Sullivan KM, Ott SM, Seidel K, Fink JC, Longton G, Sherrard DJ 2001 Bone density loss after allogeneic hematopoietic stem cell transplantation: a prospective study. Biol Blood Marrow Transplant 7:257264 17. Sklar C, Boulad F, Small T, Kernan N 2001 Endocrine complications of pediatric stem cell transplantation. Front Biosci 6:G17G22 18. Schimmer AD, Mah K, Bordeleau L, Cheung A, Ali V, Falconer M, Trus M, Keating A 2001 Decreased bone mineral density is common after autologous blood or marrow transplantation. Bone Marrow Transplant 28:387391 19. Nysom K, Holm K, Michaelsen KF, Hertz H, Jacobsen N, Muller J, Molgaard C 2000 Bone mass after allogeneic BMT for childhood leukaemia or lymphoma. Bone Marrow Transplant 25:191196 20. Bhatia S, Ramsay NK, Weisdorf D, Griffiths H, Robison LL 1998 Bone mineral density in patients undergoing bone marrow transplantation for myeloid malignancies. Bone Marrow Transplant 22:8790 21. Daniels MW, Wilson DM, Paguntalan HG, Hoffman AR, Bachrach LK 2003 Bone mineral density in pediatric transplant recipients. Transplantation 76: 673 678 22. Kaste SC, Shidler TJ, Tong X, Srivastava DK, Rochester R, Hudson MM, Shearer PD, Hale GA 2004 Bone mineral density and osteonecrosis in survivors of childhood allogeneic bone marrow transplantation. Bone Marrow Transplant 33:435 441 23. Marshall WA, Tanner JM 1969 Variations in pattern of pubertal changes in girls. Arch Dis Child 44:291303 24. Marshall WA, Tanner JM 1970 Variations in the pattern of pubertal changes in boys. Arch Dis Child 45:1323 25. Boot AM, de Ridder MA, Pols HA, Krenning EP, de Muinck Keizer-Schrama SM 1997 Bone mineral density in children and adolescents: relation to puberty, calcium intake, and physical activity. J Clin Endocrinol Metab 82:57 62 26. Writing Group for the ISCD Position Development Conference 2004 Diagnosis of osteoporosis in men, premenopausal women, and children. J Clin Densitom 7:1726 27. Aubin JE 1998 Advances in the osteoblast lineage. Biochem Cell Biol 76:899 910 28. Greulich WW, Pyle SI 1959 Radiographic atlas of skeletal development of the hand and wrist. Stanford, CA: Stanford University Press 29. Laird NM, Ware JH 1982 Random-effects models for longitudinal data. Biometrics 38:963974 30. Breiman L, Friedman JH, Olshen RA, Stone CJ 1984 Classification and regression trees. Belmont, CA: Wadsworth 31. Specker BL, Schoenau E 2005 Quantitative bone analysis in children: current methods and recommendations. J Pediatr 146:726 731 32. Mattano Jr LA 2004 Strategic approaches to osteoporosis in transplantation. Pediatr Transplant 8(Suppl 5):5155 33. Goulding A, Jones IE, Taylor RW, Manning PJ, Williams SM 2000 More broken bones: a 4-year double cohort study of young girls with and without distal forearm fractures. J Bone Miner Res 15:20112018

Petryk et al. Bone Metabolism after Bone Marrow Transplant

J Clin Endocrinol Metab, March 2006, 91(3):899 905

905

34. Schott AM, Cormier C, Hans D, Favier F, Hausherr E, Dargent-Molina P, Delmas PD, Ribot C, Sebert JL, Breart G, Meunier PJ 1998 How hip and whole-body bone mineral density predict hip fracture in elderly women: the EPIDOS Prospective Study. Osteoporos Int 8:247254 35. Marshall D, Johnell O, Wedel H 1996 Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 312: 1254 1259 36. Brandenburg VM, Westenfeld R, Ketteler M 2004 The fate of bone after renal transplantation. J Nephrol 17:190 204 37. Tauchmanova L, Serio B, Del Puente A, Risitano AM, Esposito A, De Rosa

G, Lombardi G, Colao A, Rotoli B, Selleri C 2002 Long-lasting bone damage detected by dual-energy x-ray absorptiometry, phalangeal osteosonogrammetry, and in vitro growth of marrow stromal cells after allogeneic stem cell transplantation. J Clin Endocrinol Metab 87:5058 5065 38. Galotto M, Berisso G, Delfino L, Podesta M, Ottaggio L, Dallorso S, Dufour C, Ferrara GB, Abbondandolo A, Dini G, Bacigalupo A, Cancedda R, Quarto R 1999 Stromal damage as consequence of high-dose chemo/radiotherapy in bone marrow transplant recipients. Exp Hematol 27:1460 1466 39. Sochett EB, Makitie O 2005 Osteoporosis in chronically ill children. Ann Med 37:286 294

JCEM is published monthly by The Endocrine Society (http://www.endo-society.org), the foremost professional society serving the endocrine community.

The Twenty-Fifth Annual University of Kentucky Symposium in Reproductive Sciences and Womens Health
May 18 19, 2006 This annual symposium of the Reproductive Sciences Forum at the University of Kentucky brings faculty, clinicians, and trainees in the field of reproductive sciences and womens health together to exchange information and ideas with each other and with recognized leaders of the reproductive sciences research community. The program consists of plenary lectures, a poster session, meet-the-professor luncheon and dinner. For registration information visit our web site at http://www2.mc.uky.edu/OBG/Forum/Symposium/Home.htm. Or contact: Michael Kilgore, PhD Symposium Director Department of Molecular and Biomedical Pharmacology University of Kentucky Lexington, KY 40536 Tel: (859) 323-1821 E-mail: M.Kilgore@uky.edu